Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77,143,980
-
Total 13F shares
-
67,877,304
-
Share change
-
+2,519,885
-
Total reported value
-
$1,525,459,447
-
Put/Call ratio
-
69%
-
Price per share
-
$22.47
-
Number of holders
-
170
-
Value change
-
+$59,100,303
-
Number of buys
-
91
-
Number of sells
-
86
Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q3 2024
As of 30 Sep 2024,
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) was held by
170 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,877,304 shares.
The largest 10 holders included
BlackRock, Inc., Redmile Group, LLC, VANGUARD GROUP INC, BAKER BROS. ADVISORS LP, Deep Track Capital, LP, WELLINGTON MANAGEMENT GROUP LLP, PRICE T ROWE ASSOCIATES INC /MD/, T. Rowe Price Investment Management, Inc., STATE STREET CORP, and ARK Investment Management LLC.
This page lists
170
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.